Raman-guided subcellular pharmaco-metabolomics for metastatic melanoma cells
Abstract
Non-invasively probing metabolites within single live cells is highly desired but challenging. Here we utilize Raman spectro-microscopy for spatial mapping of metabolites within single cells, with the specific goal of identifying druggable metabolic susceptibilities from a series of patient-derived melanoma cell lines. Each cell line represents a different characteristic level of cancer cell de-differentiation. First, with Raman spectroscopy, followed by stimulated Raman scattering (SRS) microscopy and transcriptomics analysis, we identify the fatty acid synthesis pathway as a druggable susceptibility for differentiated melanocytic cells. We then utilize hyperspectral-SRS imaging of intracellular lipid droplets to identify a previously unknown susceptibility of lipid mono-unsaturation within de-differentiated mesenchymal cells with innate resistance to BRAF inhibition. Drugging this target leads to cellular apoptosis accompanied by the formation of phase-separated intracellular membrane domains. The integration of subcellular Raman spectro-microscopy with lipidomics and transcriptomics suggests possible lipid regulatory mechanisms underlying this pharmacological treatment. Our method should provide a general approach in spatially-resolved single cell metabolomics studies.
Additional Information
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Received 21 January 2020; Accepted 14 August 2020; Published 24 September 2020. L.W. acknowledges start-up fund support from California Institute of Technology. We acknowledge the following agencies and foundations for support: NIH Grant U01 CA217655 (to J.R.H.); the Parker Institute for Cancer Immunotherapy (J.R.H. and A.R.), the WA State Andy Hill CARE Foundation (J.R.H.), and an ISB Innovator Award (Y.S.). Data availability: All the data supporting the findings of this study are available within the article and its Supplementary Information files and from the corresponding author upon reasonable request. The following databases are used: Human Reference Genome (UCSC hg 19), Gene Expression Omnibus database (GEO), Molecular Signatures Database (MSigDB). RNA-seq data have been deposited to array express with accession number of E-MTAB-8842. Source data are provided with this paper. Code availability: Custom code for the surprisal analysis of Raman spectra has previously been published and deposited on GitHub (https://github.com/mesako/Melanoma-Publication) 36. Source data are provided with this paper. These authors contributed equally: Jiajun Du, Yapeng Su. Author Contributions: L.W., J.R.H., J.D., and Y.S. conceived the study and designed the experiments. J.D., Y.S., C.Q., D.Y., K.M., D.L., A.N., and R.W. performed the experiments. J.D. and Y.S. analyzed and interpreted the data. L.W., J.R.H., A.R., and R.L. provided conceptual advice on data analysis and interpretation. L.W., J.D., J.R.H., and Y.S. wrote the manuscript. L.W. and J.R.H. supervised this study. The authors declare no competing interests. Peer review information: Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.Attached Files
Published - s41467-020-18376-x.pdf
Supplemental Material - 41467_2020_18376_MOESM1_ESM.pdf
Supplemental Material - 41467_2020_18376_MOESM2_ESM.pdf
Supplemental Material - 41467_2020_18376_MOESM3_ESM.docx
Supplemental Material - 41467_2020_18376_MOESM4_ESM.avi
Supplemental Material - 41467_2020_18376_MOESM5_ESM.xlsx
Supplemental Material - 41467_2020_18376_MOESM6_ESM.pdf
Supplemental Material - 41467_2020_18376_MOESM7_ESM.xlsx
Files
| Name | Size | Download all |
|---|---|---|
|
md5:50a10d88eeb908945135cbd855f830c2
|
198.5 kB | Download |
|
md5:5a137eb37b2935a6c6bc4460b0a2d0ac
|
3.8 MB | Download |
|
md5:97207a03cec82c20a11dabcf98b33ab0
|
5.9 MB | Preview Download |
|
md5:c6d894af453968073daf84750104ea9f
|
4.8 MB | Preview Download |
|
md5:8ffb1868f313c4c3e92b7757d6bdb4ee
|
5.9 MB | Preview Download |
|
md5:e25c874916458d612dbe70f32d3bc91c
|
13.7 kB | Download |
|
md5:d52666cef1639378860b3fa789726709
|
2.0 MB | Download |
|
md5:c596358e0d53e258aebfaa05b53b07b0
|
367.8 kB | Preview Download |
Additional details
- PMCID
- PMC7518429
- Eprint ID
- 105516
- Resolver ID
- CaltechAUTHORS:20200924-122708002
- Caltech
- NIH
- U01 CA217655
- Parker Institute for Cancer Immunotherapy
- Washington State Andy Hill CARE Foundation
- Institute for Systems Biology
- Created
-
2020-09-24Created from EPrint's datestamp field
- Updated
-
2021-11-16Created from EPrint's last_modified field